Ulcerative colitis signaling (WP5174)

Homo sapiens

Ulcerative colitis (UC) together with Crohn’s disease (CD) are both chronic inflammation disorders in the gastrointestinal (GI) tract, and subtypes of inflammatory bowel disease (IBD). This inflammatory response in the GI tract is a result of various environmental and genetic components, microorganisms, and an impaired immune system. Among those many factors, changes in the luminal environment of the colonic epithelial cells are crucial and remain to be precisely analyzed. This pathway only considered UC, in which certain pathogens are found in increased or decreased amounts, compared to healthy controls. In the upper section of the pathway, it is shown that the toll-like receptors (TLRs) recognized the components derived from microbes, such as flagellin, peptidoglycan (PGN), and lipopolysaccharide. As depicted on the left, also nucleotide-binding oligomerization domain (NOD) proteins, and antigen-presenting cells (APCs) recognized those microbial molecules. Activation of the TLR signaling pathway drives the upregulation of NF-kappa-B and its corresponding inflammation reaction. At the same time, the APC regulates the shift of naïve T-cells into effector T-cells and (Th2) and natural killer (NKT) T-cells. UC is mainly dominated by the Th2-type inflammation and the corresponding production of IL-4, IL-5, IL-13 and IL-10.

Authors

Susan M. Bachmann , Leonie Sieder , Ana Rodrigues , Myrte Van De Bergh , and Eric Weitz

Activity

last edited

Discuss this pathway

Check for ongoing discussions or start your own.

Cited In

Are you planning to include this pathway in your next publication? See How to Cite and add a link here to your paper once it's online.

Organisms

Homo sapiens

Communities

Annotations

Disease Ontology

inflammatory bowel disease 26 ulcerative colitis

Participants

Label Type Compact URI Comment
PGN Metabolite chebi:8005
MDP Metabolite wikidata:Q259464
TNF-α GeneProduct ensembl:ENSG00000232810
MHCII GeneProduct ensembl:ENSG00000204257
NFKB1 GeneProduct ensembl:ENSG00000109320
NOD2 GeneProduct ensembl:ENSG00000167207
TLR2 GeneProduct ensembl:ENSG00000137462
TGFB1 GeneProduct ensembl:ENSG00000105329
IL13 GeneProduct ensembl:ENSG00000169194
TGFB1 GeneProduct ensembl:ENSG00000105329
IL10 GeneProduct ensembl:ENSG00000136634
FOXP3 GeneProduct ensembl:ENSG00000049768
yc GeneProduct ensembl:ENSG00000147168
NF-kappa-B Protein uniprot:P19838
IL-10 Protein uniprot:P22301
NFATc1 Protein uniprot:O95644
STAT6 Protein uniprot:P42226
c-maf Protein uniprot:O75444
IL-13 Protein uniprot:P35225
IL-4R subunit alpha Protein uniprot:H3BRH7
IL-4 Protein uniprot:D4HNR6
IL-5 Protein uniprot:P05113
GATA-3 Protein uniprot:P23771
IL-4 Protein uniprot:P05112
IFN-y Protein uniprot:P01579

References

  1. IL-4 production by T cells from naive donors. IL-2 is required for IL-4 production. Ben-Sasson SZ, Le Gros G, Conrad DH, Finkelman FD, Paul WE. J Immunol. 1990 Aug 15;145(4):1127–36. PubMed Europe PMC Scholia
  2. Transcription: tantalizing times for T cells. Ho IC, Glimcher LH. Cell. 2002 Apr;109 Suppl:S109-20. PubMed Europe PMC Scholia
  3. Cellular and molecular immunopathogenesis of ulcerative colitis. Zhang SZ, Zhao XH, Zhang DC. Cell Mol Immunol. 2006 Feb;3(1):35–40. PubMed Europe PMC Scholia
  4. Therapeutic impact of toll-like receptors on inflammatory bowel diseases: a multiple-edged sword. Cario E. Inflamm Bowel Dis. 2008 Mar;14(3):411–21. PubMed Europe PMC Scholia
  5. Ulcerative colitis. Ordás I, Eckmann L, Talamini M, Baumgart DC, Sandborn WJ. Lancet. 2012 Nov 3;380(9853):1606–19. PubMed Europe PMC Scholia
  6. STAT6 deficiency ameliorates severity of oxazolone colitis by decreasing expression of claudin-2 and Th2-inducing cytokines. Rosen MJ, Chaturvedi R, Washington MK, Kuhnhein LA, Moore PD, Coggeshall SS, et al. J Immunol. 2013 Feb 15;190(4):1849–58. PubMed Europe PMC Scholia
  7. Innate and adaptive immunity in inflammatory bowel disease. Geremia A, Biancheri P, Allan P, Corazza GR, Di Sabatino A. Autoimmun Rev. 2014 Jan;13(1):3–10. PubMed Europe PMC Scholia
  8. IL-33 promotes GATA-3 polarization of gut-derived T cells in experimental and ulcerative colitis. Seidelin JB, Coskun M, Kvist PH, Holm TL, Holgersen K, Nielsen OH. J Gastroenterol. 2015 Feb;50(2):180–90. PubMed Europe PMC Scholia
  9. Role of regulatory T cell in the pathogenesis of inflammatory bowel disease. Yamada A, Arakaki R, Saito M, Tsunematsu T, Kudo Y, Ishimaru N. World J Gastroenterol. 2016 Feb 21;22(7):2195–205. PubMed Europe PMC Scholia
  10. Cells of the innate and adaptive immunity and their interactions in inflammatory bowel disease. Kmieć Z, Cyman M, Ślebioda TJ. Adv Med Sci. 2017 Mar;62(1):1–16. PubMed Europe PMC Scholia
  11. Interleukin 13-mediated colitis in the absence of IL-4Rα signalling. Hoving JC, Cutler AJ, Leeto M, Horsnell WGC, Dewals BG, Nieuwenhuizen NE, et al. Gut. 2017 Nov;66(11):2037–9. PubMed Europe PMC Scholia
  12. Immune response and inflammatory pathway of ulcerative colitis. Tatiya-Aphiradee N, Chatuphonprasert W, Jarukamjorn K. J Basic Clin Physiol Pharmacol. 2018 Dec 19;30(1):1–10. PubMed Europe PMC Scholia
  13. New insights into the interplay between autophagy, gut microbiota and inflammatory responses in IBD. Larabi A, Barnich N, Nguyen HTT. Autophagy. 2020 Jan;16(1):38–51. PubMed Europe PMC Scholia
  14. Acetylcholinesterase Inhibitor Pyridostigmine Bromide Attenuates Gut Pathology and Bacterial Dysbiosis in a Murine Model of Ulcerative Colitis. Singh SP, Chand HS, Banerjee S, Agarwal H, Raizada V, Roy S, et al. Dig Dis Sci. 2020 Jan;65(1):141–9. PubMed Europe PMC Scholia
  15. Ferroptosis involves in intestinal epithelial cell death in ulcerative colitis. Xu M, Tao J, Yang Y, Tan S, Liu H, Jiang J, et al. Cell Death Dis. 2020 Feb 3;11(2):86. PubMed Europe PMC Scholia
  16. Translating Treg Therapy for Inflammatory Bowel Disease in Humanized Mice. Negi S, Saini S, Tandel N, Sahu K, Mishra RPN, Tyagi RK. Cells. 2021 Jul 21;10(8):1847. PubMed Europe PMC Scholia